Granted Patent
B2
US 12,496,358 · App. 18/045,805 · Granted Dec 16, 2025
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
Inventors:
Jason P. Schrum (Philadelphia, PA); Suhaib Siddiqi (Burlington, MA); Kenechi Ejebe (New York, NY)
Assignee:
ModernaTX, Inc.
A61K48/0066C07H19/10C07H21/02C07K16/00C07K16/2887C12N5/0602C12N15/102C12N15/11C12N15/1136C12N15/1138C12N15/67C12P21/00G01N33/559C07K2317/24C12N2310/3341C12N2310/335
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using thereof.
Claims (4)
1 . A method of synthesizing a messenger ribonucleic acid (mRNA), comprising the steps of:
a) providing a deoxyribonucleic acid (DNA) that encodes a protein of interest;
b) selecting a nucleotide that disrupts a binding of a major groove binding partner with the RNA, wherein the nucleotide has decreased binding affinity to the major groove binding partner selected from the group consisting of toll-like receptor (TLR) 3, TLR7, TLR8, retinoic acid-inducible gene I (RIG-I), melanoma differentiation-associated gene 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and wherein the nucleotide comprises a modification on the major groove face of the nucleobase where an atom of the major groove face of the nucleobase is replaced or substituted with a C 1 -C 6 alkyl group; and
c) contacting the provided DNA and the selected nucleotide with an RNA polymerase, under conditions such that the mRNA is synthesized.
Assignments (6)
SECURITY INTEREST
Recorded Nov 19, 2025
From: MODERNATX, INC.
To: ARES CAPITAL CORPORATION, AS AGENT
Reel/Frame 073634/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 19, 2023
From: FLAGSHIP VENTURES
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 063705/0558 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 19, 2023
From: SIDDIQI, SUHAIB
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 063705/0687 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 19, 2023
From: EJEBE, KENECHI
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 063705/0728 →
EMPLOYMENT AGREEMENT
Recorded May 19, 2023
From: SCHRUM, JASON P.
To: MODERNA THERAPEUTICS, INC.
Reel/Frame 063706/0703 →
CHANGE OF NAME
Recorded May 19, 2023
From: MODERNA THERAPEUTICS, INC.
To: MODERNATX, INC.
Reel/Frame 063709/0143 →
Continuity (8)
Continuation
13251840
· Oct 3, 2011
Provisional Application
61404413
· Oct 1, 2010
References Cited (52)
US 9334328B2
· Schrum
· 2016
[cited by examiner]
US 20240252645A1
· De Fougerolles et al.
· 2024
[cited by applicant]
EP 3112467A1
· 2017
[cited by applicant]
EP 3287525A1
· 2018
[cited by applicant]
EP 3611266B1
· 2022
[cited by applicant]
WO WO2005039551A2
· 2005
[cited by applicant]
WO WO2007024708A2
· 2007
[cited by applicant]
WO WO2007041774A1
· 2007
[cited by applicant]
WO WO2008052770A2
· 2008
[cited by applicant]
U.S. Appl. No. 61/404,413, Afeyan et al.
[cited by applicant]
U.S. Appl. No. 61/470,451, Afeyan et al.
[cited by applicant]
Alexopoulou et al., “Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3,” Nature 413:732-38 (2001).
[cited by applicant]
Berg et al., Chapter 4: DNA, RNA, and the Flow of Genetic Information.
[cited by applicant]
Berry & Associates, 2009 Product Catalog, downloaded Sep. 3, 2024 (288 pages).
[cited by applicant]
Charette et al., “Pseudouridine in RNA: What, Where, How, and Why,” IUBMB Life 49(5);341-51 (2000).
[cited by applicant]
Conrad et al., “Enzymatic synthesis of 2′-modified nucleic acids: identification of important phosphate and ribose moieties in RNase P substrates,” Nucleic Acids Res 23(11):1845-53 (1995).
[cited by applicant]
De Wet et al., “Firefly Luciferase Gene: Structure and Expression in Mammalian Cells,” Mol Cell Bio 7(2):725-37 (1987).
[cited by applicant]
Diebold et al., “Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA,” Science. 303(5663): 1529-31 (2004).
[cited by applicant]
Feng et al., “MDA5 Detects the Double-Stranded RNA Replicative Form in Picornavirus-Infected Cells,” Cell Rep 2(5);1187-96 (Nov. 2012).
[cited by applicant]
Gallie et al., “Heat Shock Disrupts Cap and Poly(A) Tail Function during Translation and Increases mRNA Stability of Introduced Reporter mRNA,” Plant Physiol 108(4):1703-13 (1995).
[cited by applicant]
Gallie et al., “Post-transcriptional regulation in higher eukaryotes: The role of the reporter gene in controlling expression,” Mol Gen Genet 228:258-64 (1991).
[cited by applicant]
Hames et al., Processing of Eukaryotic Pre-mRNA.
[cited by applicant]
Heil et al., “Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8.”
[cited by applicant]
Helm, M., “Post-transcriptional nucleotide modification and alternative folding of RNA,” Nucleic Acids Res 34(2):721-33 (2006).
[cited by applicant]
Ivanov et al., “RNA Synthesis by T7 Rna Polymerase Supported Primer Extension,” J Mol Biol 38(5):674-9 (2004).
[cited by applicant]
Karikó et al., “Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability,” Mol Ther. 16(11):1833-40 (2008).
[cited by applicant]
Karikó et al., Supplementary material for “Incorporation of Pseudouridine in mRNA Yields Superior Nonimmunogenic Vector with Increased Translational Capacity and Biological Stability,” Mol Ther 16(11):1833-40 (2008) (4 …
[cited by applicant]
Kozak, M., “Regulation of translation via mRNA structure in prokaryotes and eukaryotes,” Gene 361:13-37 (2005).
[cited by applicant]
Limbach et al., “Summary: the modifiers nucleosides of RNA,” Nucleic Acids Res. 22(12):2183-96 (1994).
[cited by applicant]
Matsumoto et al., “Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling,” Biochem Biophys Res Commun 293(5):1364-9 (2002).
[cited by applicant]
McCloskey et al., “Post-transcriptional modification in archaeal tRNAs: identities and phylogenetic relations of nucleotides from mesophilic and hyperthermophilic
[cited by applicant]
Milligan et al., Synthesis of Small RNAs Using T7 Rna Polymerase.
[cited by applicant]
MMESSAGE mMACHINE Kit Product Manual, Ambion/Invitrogen. Last revised Jan. 4, 2007 (34 pages).
[cited by applicant]
Motorin et al., “Appendix 1: Chemical Structures and Classification of Posttranscriptionally Modified Nucleosides in RNA,”
[cited by applicant]
Newby et al., “Investigation of Overhauser effects between pseudouridine and water protons in RNA helices,” Proc Natl Acad Sci 99(20):12697-702 (2002) (6 pages).
[cited by applicant]
Oliva et al., “Accurate energies of hydrogen bonded nucleic acid base pairs and triplets in tRNA tertiary interactions,” Nucleic Acids Res 34(3):865-79 (2006).
[cited by applicant]
Pascolo, Chapter 3: Vaccination With Messenger RNA.
[cited by applicant]
Pascolo, S. Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol. 2008; 183:221-235.
[cited by applicant]
Pelletier et al., “The involvement of mRNA secondary structure in protein synthesis,” Biochem Cell Biol 65(6):576-81 (1987).
[cited by applicant]
R&D Systems, ELISA Catalog & Reference Guide 2007, downloaded Sep. 3, 2024 (60 pages).
[cited by applicant]
Rehm et al., 5b Mutations,
[cited by applicant]
Song et al., “m
[cited by applicant]
Sprinzl et al., “Compilation of tRNA sequences and sequences of tRNA genes,” Nucleic Acids Res 26(1):148-53 (1998).
[cited by applicant]
Williams et al., “Messenger Nucleic Acids.”
[cited by applicant]
Wurm et al., “The ribosome assembly factor Nep1 responsible for Bowen-Conradi syndrome is a pseudouridine-N1-specific methyltransferase,” Nucleic Acids Res 38(7):2387-98 (Apr. 2010).
[cited by applicant]
Zhou et al., “Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase,” Mol Cell Biol 10(9):4529-37 (1990).
[cited by applicant]